Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
CPEX Pharmaceuticals, Inc. (CPEX)
|
Add to portfolio |
|
|
|
| Price: |
$23.99
| | Metrics |
| OS: |
2.62
|
M
| |
24
|
% ROE
|
| Market cap: |
$62.8
|
M
| |
|
|
|
Net cash:
|
$22.2
|
M
| |
$8.47
|
per share
|
|
EV:
|
$40.6
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$7.0
|
M
| |
5.8
|
x EV/EBITDA
|
|
EBIT
|
$6.3
|
M
| |
6.4
|
x EV/EBIT
|
| EPS |
$1,482.98
| |
0.0
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 |
| Revenues | 40.3 | 40.5 | 15.6 | 11.1 | 8.4 |
| Revenue growth | -0.6% | 160.1% | 40.0% | 33.0% | |
| Cost of goods sold | 17.0 | 21.9 | 0.0 | 0.0 | 0.0 |
| Gross profit | 23.3 | 18.7 | 15.6 | 11.1 | 8.4 |
| Gross margin | 57.8% | 46.1% | 100.0% | 100.0% | 100.0% |
| Research and development | 7.5 | 12.3 | 9.1 | 9.6 | 7.9 |
| General and administrative | 8.8 | 8.9 | 6.5 | 5.2 | 4.7 |
| EBIT | 6.3 | -3.2 | -3.2 | -5.5 | -4.8 |
| EBIT margin | 15.7% | -7.9% | -20.7% | -49.3% | -57.9% |
| Pre-tax income | 6.4 | -3.0 | -2.9 | -4.9 | -4.2 |
| Income taxes | -0.2 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | 6.6 | -3.0 | -2.9 | -4.9 | -4.2 |
| Net margin | 16.5% | -7.5% | -18.7% | -44.3% | -49.7% |
| |
| Diluted EPS | $2,459.43 | ($1,210.67) | ($1.25) | ($2.17) | ($1.83) |
| Shares outstanding (diluted) | 0.0 | 0.0 | 2.3 | 2.3 | 2.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|